MX341132B - Compuesto (tieno [2-3-b] [1,5] benzoxazepin-4-il) piperazin-1-ilo como agonista h1 inversos/antagonistas 5-ht2a de actividad doble. - Google Patents
Compuesto (tieno [2-3-b] [1,5] benzoxazepin-4-il) piperazin-1-ilo como agonista h1 inversos/antagonistas 5-ht2a de actividad doble.Info
- Publication number
- MX341132B MX341132B MX2014000337A MX2014000337A MX341132B MX 341132 B MX341132 B MX 341132B MX 2014000337 A MX2014000337 A MX 2014000337A MX 2014000337 A MX2014000337 A MX 2014000337A MX 341132 B MX341132 B MX 341132B
- Authority
- MX
- Mexico
- Prior art keywords
- benzoxazepin
- thieno
- piperazin
- compounds
- inverse agonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Se describen un antagonista de receptor H1/5-HT2A doble de la fórmula, sus usos, y métodos para su preparación.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161505685P | 2011-07-08 | 2011-07-08 | |
| PCT/US2012/045254 WO2013009517A1 (en) | 2011-07-08 | 2012-07-02 | (THIENO[2,3-b][1,5]BENZOXAZEPIN-4-YL)PIPERAZIN-1-YL COMPOUNDS AS DUAL ACTIVITY H1 INVERSE AGONISTS/5-HT2A ANTAGONISTS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014000337A MX2014000337A (es) | 2014-11-13 |
| MX341132B true MX341132B (es) | 2016-08-09 |
Family
ID=46513872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014000337A MX341132B (es) | 2011-07-08 | 2012-07-02 | Compuesto (tieno [2-3-b] [1,5] benzoxazepin-4-il) piperazin-1-ilo como agonista h1 inversos/antagonistas 5-ht2a de actividad doble. |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9481688B2 (es) |
| EP (1) | EP2729474B1 (es) |
| JP (1) | JP6050813B2 (es) |
| KR (1) | KR101582429B1 (es) |
| CN (1) | CN103703008B (es) |
| AU (1) | AU2012283035B2 (es) |
| BR (1) | BR112014000379A2 (es) |
| CA (1) | CA2840217C (es) |
| DK (1) | DK2729474T3 (es) |
| EA (1) | EA023460B1 (es) |
| ES (1) | ES2665035T3 (es) |
| HR (1) | HRP20180475T1 (es) |
| HU (1) | HUE037649T2 (es) |
| IN (1) | IN2014MN00144A (es) |
| LT (1) | LT2729474T (es) |
| MX (1) | MX341132B (es) |
| NO (1) | NO2729474T3 (es) |
| PL (1) | PL2729474T3 (es) |
| PT (1) | PT2729474T (es) |
| RS (1) | RS57207B1 (es) |
| SI (1) | SI2729474T1 (es) |
| WO (1) | WO2013009517A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2893106C (en) | 2013-01-14 | 2017-07-18 | Eli Lilly And Company | (thieno[2,3-b][1,5]benzoxazepin-4-yl)piperazin-1-yl compounds as dual activity h1 inverse agonists/5-ht2a antagonists |
| TW201625644A (zh) | 2014-04-29 | 2016-07-16 | 美國禮來大藥廠 | 作為選擇性５－ＨＴＡ反向促效劑之（噻吩并［２，３－ｂ］［１，５］苯并氧氮呯－４－基）哌嗪－１－基化合物 |
| WO2018166855A1 (en) | 2017-03-16 | 2018-09-20 | Basf Se | Heterobicyclic substituted dihydroisoxazoles |
| CN108371660B (zh) * | 2017-12-14 | 2020-03-10 | 五邑大学 | 一种四氢环戊二烯并吡咯化合物及其衍生物的用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5602124A (en) * | 1994-12-12 | 1997-02-11 | Allelix Biopharmaceuticals, Inc. | 5-HT2 receptor ligands |
| JP2003510322A (ja) * | 1999-09-29 | 2003-03-18 | イーライ・リリー・アンド・カンパニー | 再取り込みインヒビターとしてのピペリジン誘導体 |
| HU226410B1 (en) * | 2003-04-22 | 2008-11-28 | Egis Gyogyszergyar Nyilvanosan | Novel polymorphous forms of olanzapine hydrochlorides, process for producing them, use thereof and pharmaceutical compositions containing them |
| US7807828B2 (en) * | 2005-08-11 | 2010-10-05 | Hypnion, Inc. | Olanzapine analogs and methods of use thereof |
| JP5421787B2 (ja) * | 2007-03-15 | 2014-02-19 | アンダマン セラピューティクス、インコーポレイテッド | ジベンゾ［ｂ，ｆ］［１，４］オキサザピン化合物 |
| KR102184038B1 (ko) * | 2008-05-27 | 2020-11-27 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 수면 장애 및 다른 장애를 치료하기 위한 방법 및 조성물 |
| GB0910009D0 (en) * | 2009-06-10 | 2009-07-22 | Glaxo Group Ltd | Novel compounds |
| AR084867A1 (es) * | 2011-02-07 | 2013-07-10 | Lilly Co Eli | Compuestos de acido [(5h-pirrolo[2,1-c][1,4]benzodiazepin-11-il)piperazin-1-il]-2,2-dimetilpropanoico sustituido como antagonistas de 5-ht/agonistas inversos de actividad dual |
| PL2751115T3 (pl) * | 2011-08-30 | 2018-02-28 | Eli Lilly And Company | Związki (tieno[2,3-b][1,5]benzoksazepin-4-ylo)piperazyn-1-ylowe o podwójnym działaniu jako odwrotni agoniści receptora H1 / antagoniści receptora 5-HT2A |
-
2012
- 2012-07-02 NO NO12735409A patent/NO2729474T3/no unknown
- 2012-07-02 CN CN201280031201.7A patent/CN103703008B/zh active Active
- 2012-07-02 LT LTEP12735409.0T patent/LT2729474T/lt unknown
- 2012-07-02 PT PT127354090T patent/PT2729474T/pt unknown
- 2012-07-02 ES ES12735409.0T patent/ES2665035T3/es active Active
- 2012-07-02 SI SI201231263T patent/SI2729474T1/en unknown
- 2012-07-02 DK DK12735409.0T patent/DK2729474T3/en active
- 2012-07-02 AU AU2012283035A patent/AU2012283035B2/en not_active Ceased
- 2012-07-02 BR BR112014000379A patent/BR112014000379A2/pt not_active IP Right Cessation
- 2012-07-02 KR KR1020147000119A patent/KR101582429B1/ko active IP Right Grant
- 2012-07-02 JP JP2014519227A patent/JP6050813B2/ja active Active
- 2012-07-02 PL PL12735409T patent/PL2729474T3/pl unknown
- 2012-07-02 EA EA201391706A patent/EA023460B1/ru not_active IP Right Cessation
- 2012-07-02 EP EP12735409.0A patent/EP2729474B1/en active Active
- 2012-07-02 RS RS20180568A patent/RS57207B1/sr unknown
- 2012-07-02 CA CA2840217A patent/CA2840217C/en not_active Expired - Fee Related
- 2012-07-02 US US14/125,320 patent/US9481688B2/en active Active
- 2012-07-02 HU HUE12735409A patent/HUE037649T2/hu unknown
- 2012-07-02 MX MX2014000337A patent/MX341132B/es active IP Right Grant
- 2012-07-02 WO PCT/US2012/045254 patent/WO2013009517A1/en active Application Filing
-
2014
- 2014-01-23 IN IN144MUN2014 patent/IN2014MN00144A/en unknown
-
2018
- 2018-03-21 HR HRP20180475TT patent/HRP20180475T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20180475T1 (hr) | 2018-06-15 |
| JP2014518280A (ja) | 2014-07-28 |
| DK2729474T3 (en) | 2018-05-22 |
| EA201391706A1 (ru) | 2014-04-30 |
| BR112014000379A2 (pt) | 2017-01-10 |
| ES2665035T3 (es) | 2018-04-24 |
| CA2840217C (en) | 2016-03-22 |
| NO2729474T3 (es) | 2018-08-11 |
| US9481688B2 (en) | 2016-11-01 |
| JP6050813B2 (ja) | 2016-12-21 |
| KR20140029512A (ko) | 2014-03-10 |
| EP2729474A1 (en) | 2014-05-14 |
| EP2729474B1 (en) | 2018-03-14 |
| MX2014000337A (es) | 2014-11-13 |
| AU2012283035A1 (en) | 2014-01-16 |
| EA023460B1 (ru) | 2016-06-30 |
| LT2729474T (lt) | 2018-05-10 |
| PT2729474T (pt) | 2018-06-05 |
| CA2840217A1 (en) | 2013-01-17 |
| WO2013009517A1 (en) | 2013-01-17 |
| SI2729474T1 (en) | 2018-04-30 |
| CN103703008B (zh) | 2015-11-25 |
| US20140121199A1 (en) | 2014-05-01 |
| CN103703008A (zh) | 2014-04-02 |
| KR101582429B1 (ko) | 2016-01-04 |
| AU2012283035B2 (en) | 2015-07-30 |
| PL2729474T3 (pl) | 2018-08-31 |
| RS57207B1 (sr) | 2018-07-31 |
| HUE037649T2 (hu) | 2018-09-28 |
| IN2014MN00144A (es) | 2015-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2014002473A (es) | Compuestos (tieno [2,3-b] [1,5] benzoxazepin -4 -il) piperazin- 1 - ilo como angonistas inversos h1 / antagonistas 5 -ht2a de actividad doble. | |
| UA111640C2 (uk) | ПОХІДНІ [1,2,3]ТРИАЗОЛО[4,5-d]ПІРИМІДИНУ ЯК АГОНІСТИ КАНАБІНОЇДНОГО РЕЦЕПТОРА 2 | |
| MY160665A (en) | Spiropiperidine compounds as orl-1 receptor antagonists | |
| PH12014501026A1 (en) | [1, 2, 3]triazolo[4,5-d] pyrimidine derivatives as agonists of the cannabinoid receptor 2 agonists | |
| HRP20180475T1 (hr) | (TIENO[2,3-b][1,5]BENZOKSAZEPIN-4-IL)PIPERAZIN-1-ILNI SPOJEVI, DVOJNO AKTIVNI KAO INVERZNI AGONISTI H1/ANTAGONISTI 5-HT2A | |
| PH12013500991A1 (en) | 4-SUBSTITUTED-3-PHENYLSULFANYLMETHYL-BICYCLO[3.1.0]HEXANE COMPOUNDS AS mGLuR 2/3 ANTAGONISTS | |
| MX2015008970A (es) | Compuestos de (tieno [2,3-b] [1,5] benzoxazepin-4-il) piperazin-1-ilo de actividad doble como agonista inversos de h1/antagonistas de 5-ht2a. | |
| TN2013000209A1 (en) | 4-substituted-3-phenylsulfanylmethyl-bicyclo[3.1.0]hexane compounds as mglur 2/3 antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |